XASX
IMR
Market cap327mUSD
Jun 18, Last price
1.87AUD
1D
-1.06%
1Q
-4.10%
IPO
52.03%
Name
Imricor Medical Systems Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Imricor Medical Systems, Inc. operates as a specialized medical device company focused on developing, manufacturing, and commercializing products that are fully compatible with Magnetic Resonance Imaging (MRI) technology. These devices are specifically designed for use in cardiac catheter ablation procedures performed across the United States. The company's primary product portfolio includes the Advantage-MR EP Recorder/Stimulator system, which functions as both an electrophysiology recording system and an integrated cardiac stimulator. Another key offering is the Vision-MR Ablation Catheter, indicated for the treatment of type I atrial flutter. Imricor also provides the Vision-MR Dispersive Electrode, engineered to minimize eddy currents that can occur on conductive pads during an MRI scan. Beyond its core product development, Imricor engages in contract research activities and licenses its proprietary intellectual property for incorporation into implantable medical devices. Established in 2006, the firm's corporate headquarters are situated in Burnsville, Minnesota.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||